---
schema_version: "secwatch.filing_event.v1"
accession: "0001384101-22-000004"
form_type: "8-K"
ticker: "VCYT"
cik: "0001384101"
company_name: "VERACYTE, INC."
filed_at: "2022-01-11T23:59:59+00:00"
generated_at: "2026-06-27T18:53:59.762998+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Veracyte appoints Tina Nova as President of CLIA U.S. business

## Summary
- Tina S. Nova, Ph.D., appointed President of Veracyte's CLIA U.S. business effective January 6, 2022.
- Dr. Nova previously served as General Manager, Thyroid and Urologic Cancers since March 2021.
- She was on Veracyte's board from Nov 2015 to Feb 2021 and was CEO of Decipher before its acquisition.
- Dr. Nova will enter into standard indemnification agreement; no family relationships or material transactions disclosed.

## SEC filing metadata
- accession: 0001384101-22-000004
- form_type: 8-K
- ticker: VCYT
- cik: 0001384101
- company_name: VERACYTE, INC.
- filed_at: 2022-01-11T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1384101/000138410122000004/0001384101-22-000004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1384101/000138410122000004/vcyt-20220106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001384101-22-000004
- JSON: https://secwatch.observer/filing/0001384101-22-000004.json
- Plain text: https://secwatch.observer/filing/0001384101-22-000004.txt

## Key facts
- Executive change
  Tina S. Nova, Ph.D. was appointed as President of the Company’s CLIA U.S. business at VERACYTE, INC..
  - Action: appointed
  - Role: President of the Company’s CLIA U.S. business
  source text: On January 6, 2022, Veracyte, Inc. (the “Company”), announced certain key leadership promotions including the appointment of Tina S. Nova, Ph.D., to serve as President of the Company’s CLIA U.S. business, effective as of January 6, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1384101/000138410122000004/0001384101-22-000004-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.